Skip to main content

Morgan Stanley Remains a Hold on Zimmer Biomet Holdings (ZBH)

Tipranks - Tipranks - Tue Feb 3, 8:00AM CST

Morgan Stanley analyst Patrick Wood maintained a Hold rating on Zimmer Biomet Holdings today and set a price target of $100.00.

Claim 50% Off TipRanks Premium

Wood covers the Healthcare sector, focusing on stocks such as Alphatec Holdings, Dexcom, and Tandem Diabetes Care. According to TipRanks, Wood has an average return of 2.0% and a 56.88% success rate on recommended stocks.

In addition to Morgan Stanley, Zimmer Biomet Holdings also received a Hold from TipRanks – Google’s Google Medical – Devices in a report issued yesterday. However, on January 30, TD Cowen upgraded Zimmer Biomet Holdings (NYSE: ZBH) to a Buy.

See the top stocks recommended by analysts >>

Based on Zimmer Biomet Holdings’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $2 billion and a net profit of $230.9 million. In comparison, last year the company earned a revenue of $1.82 billion and had a net profit of $249.1 million

Read More on ZBH:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).